Skip to main content

Table 2 Dose-limiting toxicities at cycle 1 and adverse events at subsequent cycles

From: Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

DLTs at the first cycle (n = 3)
Dose level, mg/m 2 Patients, n Event
8.4
10 1 Grade 3 diarrhoea
12 2 Grade 3 diarrhoea (both patients)
Adverse events at cycles ≥ 2 (n = 13)
Dose level, mg/m 2 Patients, n Event
8.4 4 Grade 3 asthenia (three patients)
Grade 3 diarrhoea
10 1 Grade 3 haematuria
  Grade 3 dysuria
12 3 Grade 3 asthenia (two patients)
Febrile neutropenia
Neutropenia Grade 4 for > 5 days (two patients)
Grade 3 diarrhoea
   Grade 3 asthenia